Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04590248 | A Study of Adavosertib as Treatment for Uterine Serous Carcinoma | PHASE2 | COMPLETED | 109 | — | — | Nov 30, 2020 | Feb 7, 2023 | Aug 14, 2023 | 27 | United States, Canada +3 |
Per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 for target lesions (TLs) and assessed by computed tomography (CT) or magnetic resonance imaging (MRI): Complete response (CR), Disappearance of all target lesions; Partial response (PR), \>=30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.
| Arm | Type | Description |
|---|---|---|
| Adavosertib | EXPERIMENTAL | Subjects will receive adavosertib 300 mg administered orally, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle. |
| Name | Type | Description |
|---|---|---|
| Adavosertib | DRUG | The subjects will receive oral adavosertib 300 mg, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle. |
Inclusion Criteria: 1. Subjects must be aged ≥ 18 years of age inclusive, at the time of signing the informed consent. 2. Histologically confirmed recurrent or persistent USC. Subjects with carcinosarcomas are not eligible. 3. Evidence of measurable disease as per RECIST v1.1. 4. At least 1 prior p...